HitGen Inc
SSE:688222
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (77), the stock would be worth ¥16.93 (37% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 121.9 | ¥26.81 |
0%
|
| 3-Year Average | 77 | ¥16.93 |
-37%
|
| 5-Year Average | 106.8 | ¥23.49 |
-12%
|
| Industry Average | 26.8 | ¥5.88 |
-78%
|
| Country Average | 28.8 | ¥6.34 |
-76%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥11.8B
|
/ |
Apr 2025
¥89.1m
|
= |
|
|
¥11.8B
|
/ |
Dec 2025
¥166m
|
= |
|
|
¥11.8B
|
/ |
Dec 2026
¥198.6m
|
= |
|
|
¥11.8B
|
/ |
Dec 2027
¥236.3m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
HitGen Inc
SSE:688222
|
10.8B CNY | 121.9 | 163.6 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 226.4 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
176.7B USD | 18.4 | 26.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
125.4B USD | 17.6 | 34 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 30.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.9B CNY | 16.3 | 15.6 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.3B CHF | 16.1 | -118.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 18.6 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.4B USD | 30.5 | 47.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.5B USD | 11.5 | 20.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.1B USD | 22.3 | 30 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
HitGen Inc
Glance View
HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. The company is headquartered in Chengdu, Sichuan and currently employs 508 full-time employees. The company went IPO on 2020-04-16. The firm focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The firm mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The firm conducts its businesses within the domestic market and to overseas markets.
